MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Visipaque (iodixanol)

Company: Nycomed
Approval Status: Approved April 1996
Treatment for: diagnosis of disease in major organs
Areas: Cardiovascular / Cardiology; Gastrointestinal; Hematology; Urology & Kidneys; Neurology & Nervous System; Cancer & Oncology; Respiratory

| General Information | Additional Information |


General Information

Visipaque is a contrast agent that allows doctors to better diagnose diseases of the heart, brain, kidney, blood vessels and other major organs.


Additional Information

Contrast agents, in general, are fluids that are injected into a subject's blood stream to enhance the images, or pictures, of certain body organ structures or processes obtained during diagnostic imaging procedures. This enhancement enables physicians to more accurately detect, diagnose, and properly treat disease, states, and functional abnormalities, such as tumors and cardiovascular disorders.

Each year, as many as 18 million subjects in the United States undergo X-rays and other diagnostic procedures that require the administration of contrast media to aid in the detailed visualization of internal organs and tissues.




< back to top

Visipaque Drug Information

The Visipaque drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.